Certara, Inc. (NASDAQ:CERT – Get Free Report) has been assigned a consensus rating of “Moderate Buy” from the eight research firms that are presently covering the firm, Marketbeat Ratings reports. Four investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $15.83.
Several analysts have issued reports on the stock. Stephens restated an “overweight” rating and set a $17.00 price target on shares of Certara in a research report on Thursday, February 27th. Barclays upped their price target on shares of Certara from $12.00 to $13.00 and gave the company an “equal weight” rating in a research report on Friday, February 28th. William Blair restated a “market perform” rating on shares of Certara in a research report on Thursday, February 27th. Finally, TD Cowen assumed coverage on shares of Certara in a research report on Thursday, February 27th. They set a “buy” rating and a $16.00 price target for the company.
Read Our Latest Stock Report on CERT
Institutional Trading of Certara
Certara Stock Up 0.5 %
Shares of NASDAQ:CERT opened at $11.91 on Thursday. Certara has a 52-week low of $9.41 and a 52-week high of $19.87. The firm has a fifty day moving average of $12.52 and a 200 day moving average of $11.63. The firm has a market capitalization of $1.92 billion, a PE ratio of -59.55, a price-to-earnings-growth ratio of 9.29 and a beta of 1.60. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.86 and a current ratio of 2.86.
About Certara
Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.
Read More
- Five stocks we like better than Certara
- What is the Nikkei 225 index?
- Corporate Crawl: Where Business Trips Turn Into Party Nights
- Earnings Per Share Calculator: How to Calculate EPS
- CrowdStrike’s Growth Remains Strong—Buy While It’s Down
- What Are Dividends? Buy the Best Dividend Stocks
- Is Advanced Micro Devices Stock Slide Over?
Receive News & Ratings for Certara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Certara and related companies with MarketBeat.com's FREE daily email newsletter.